21 October 2020 - Familial chylomicronaemia syndrome is a rare and potentially life-threatening condition that has a significant effect on the quality of life of people with the condition, and their families and carers.

Volanesorsen sodium is recommended, within its marketing authorisation, as an option for treating familial chylomicronaemia syndrome in adults with genetically confirmed familial chylomicronaemia syndrome who are at high risk of pancreatitis, and when response to diet and triglyceride-lowering therapy has been inadequate. 

It is recommended only if the company provides volanesorsen sodium according to the commercial arrangement.

Read NICE highly specialised technologies guidance for volanesorsen